Guilford Aquavan enters Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Guilford initiates a Phase III study of its propofol prodrug Aquavan for sedation of patients undergoing colonoscopy, the firm announces Sept. 20. The 267-patient, open-label, evaluator-blinded study is the first of several in the Aquavan Phase III program. Guilford plans to seek approval for "procedural sedation for brief diagnostic and therapeutic procedures such as colonoscopy, bronchoscopy, interventional cardiology and minor surgical procedures." Aquavan's water solubility could yield advantages over propofol, which is formulated in an oil or lipid-based emulsion, Guilford claims. Advantages "may include potentially fewer side effects, such as cardiovascular side effects, elevated blood lipid levels (hyperlipidemia), increased ease of use, improved stability, reduced risk of bacterial contamination and pain upon injection"...
You may also be interested in...
Guilford's suspension of Aquavan Phase III trial enrollment to recalculate dosing levels will delay an NDA filing until the second half of 2006, the firm says
Washington State Ecology Mulls ‘Safer’ Definition While Exploring Phthalate Alternatives In Fragrances
Marissa Smith, senior regulatory toxicologist in the Washington Department of Ecology’s Hazardous Waste and Toxics Reduction program, discusses what’s next for the state’s inaugural Safer Products go-round. “How we define ‘safer’ is really going to be the lynchpin of this whole process,” she says.
Class action complaints filed in 2020 against food, dietary supplement and beverage firms should pass 2019’s total as COVID-19 has not slowed litigants but has given plaintiffs’ council more time out of court to shop for new cases.